Skip to main content
An official website of the United States government
Principal Investigator
Luis Javier Santos-Reyes
Awardee Organization

Comprehensive Cancer Center/ Univ/Pr
United States

Fiscal Year
2024
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Puerto Rico NCI Community Oncology Research Program (Puerto Rico NCORP)

The PRNCORP is the only organization that conducts significant, meaningful NCI-directed Clinical Cancer Research focused on general communities in Puerto Rico for cancer treatment, cancer control and prevention, and cancer care delivery. It is the backbone for the development of the multidisciplinary cancer care at the University of Puerto Rico Comprehensive Cancer Center (UPRCCC Hospital), which was opened to patient care on August 20, 2018. All faculty members, including translational researchers and clinical care providers, participate in the PRNCORP for the purpose of broadening the catchment base for accrual to our clinical trials. Each department within the CCCUPR Hospital, such as Gynecologic Oncology, Breast Cancer Clinic, and Hematological Malignancies Clinic, uses the PRNCORP as a platform to develop research within their respective areas of expertise. All patients treated at the CCCUPR Hospital will be consented for enrollment in PRNCORP to collect demographical and clinical data, as well as for specialized tissue donation. The PRNCORP is also a valuable source of knowledge for the broader oncology medical community. It will serve to improve cancer treatment and care for Adult and Pediatric patients throughout its participating institutions and beyond. Our PI’s and Co-PI’s are experienced professionals with over 30 years of experience in Clinical Research, with very strong staff and support personnel. Our fellows and attending are active participants in Medical Schools, tumor boards, and cancer seminars, and are involved in yearly updates to the Medical Community, such as the ASCO and ASH Review Conference. Our research environment will improve: (1) Pathology Departments, (2) Radiology Imaging Departments, (3) Radiotherapy Service, (4) Gastroenterology, (5) Surgery, (6) Hematology-Oncology Treatment Program, and (7) Direct Patient Care.

Publications

  • Kircher S, Duan F, An N, Gareen IF, Sicks JD, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Park ER, Wagner LI, Carlos RC. Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer. JAMA network open. 2024 Jan 2;7(1):e2350844. PMID: 38194233
  • Sadigh G, Duan F, An N, Gareen ID, Sicks J, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Taylor MA, Park E, Wagner LI, Kircher SM, Carlos RC. Financial Hardship Among Patients With Early-Stage Colorectal Cancer. JAMA network open. 2024 Sep 3;7(9):e2431967. PMID: 39287948
  • Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017 Dec 1;123(23):4653-4662. Epub 2017 Aug 7. PMID: 28786105